NCT01558869

Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma

An Open-label, Single-centre, Single-arm Phase II Study of Capecitabine Combined With Oxaliplatin and Irinotecan (Xeloxiri) as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 37 (actual)
• Sponsor: The University of Hong Kong · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, single centre, single-arm phase II study which aims to assess the efficacy and tolerability of triplet combination of capecitabine, oxaliplatin and irinotecan (Xeloxiri regimen) in treating patients with advanced unresectable pancreatic carcinoma. Clinical data from patients diagnosed with pancreatic adenocarcinoma will be collected and analyzed in this study. The patients' data will be collected and maintained in the Division of Medical Oncology of the University Department of Medicine, Queen Mary Hospital, Hong Kong.

Conditions

• Pancreatic Adenocarcinoma

Interventions

Type	Name	Description
DRUG	Capecitabine	1200 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)
DRUG	Oxaliplatin	70 mg/m2 IV on day 1 of a 2-week cycle
DRUG	Irinotecan	130 mg/m2 IV on day 1 of a 2-week cycle

Timeline

• Start date: 2012-04-01
• Primary completion: 2016-12-01
• Completion: 2016-12-01
• First posted: 2012-03-20
• Last updated: 2017-05-09

Locations

1 site across 1 country: Hong Kong